Stock LAB B GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genomma Lab Internacional, S.A.B. de C.V.

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
17.77 MXN -4.51% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. +6.53% +25.49%
Apr. 25 Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
Apr. 24 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 18,932 19,061 21,614 16,849 13,161 16,795 - -
Enterprise Value (EV) 1 24,043 23,381 26,264 21,719 17,681 20,241 19,624 19,683
P/E ratio 19.3 x 12.9 x 14.9 x - 13.1 x 8.08 x 8.18 x 6.42 x
Yield - - 1.78% - 1.38% - 1.88% -
Capitalization / Revenue 1.48 x 1.37 x 1.4 x 1 x 0.8 x 0.94 x 0.88 x 0.81 x
EV / Revenue 1.88 x 1.69 x 1.7 x 1.29 x 1.07 x 1.14 x 1.03 x 0.95 x
EV / EBITDA 9.35 x 7.97 x 8.18 x 6.26 x 5.12 x 5.2 x 4.63 x 4.17 x
EV / FCF 145 x 18 x 32.1 x 13.4 x 8.81 x 12.1 x 10.6 x 9.47 x
FCF Yield 0.69% 5.55% 3.11% 7.49% 11.4% 8.24% 9.46% 10.6%
Price to Book 2.38 x 2.05 x 1.96 x - 1.44 x 1.44 x 1.24 x -
Nbr of stocks (in thousands) 1,011,839 1,011,744 1,006,240 994,639 929,461 945,144 - -
Reference price 2 18.71 18.84 21.48 16.94 14.16 17.77 17.77 17.77
Announcement Date 2/26/20 2/24/21 2/23/22 2/22/23 2/21/24 - - -
1MXN in Million2MXN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 12,756 13,867 15,460 16,859 16,467 17,823 19,118 20,744
EBITDA 1 2,571 2,932 3,210 3,471 3,454 3,892 4,235 4,718
EBIT 1 2,435 2,777 3,063 3,263 3,224 3,503 3,963 4,464
Operating Margin 19.09% 20.03% 19.81% 19.35% 19.58% 19.66% 20.73% 21.52%
Earnings before Tax (EBT) 1 1,536 2,247 2,313 2,261 1,685 2,946 3,429 4,340
Net income 1 986.7 1,478 1,451 1,397 1,031 1,978 2,224 2,624
Net margin 7.74% 10.66% 9.39% 8.29% 6.26% 11.1% 11.63% 12.65%
EPS 2 0.9700 1.460 1.440 - 1.080 2.200 2.173 2.770
Free Cash Flow 1 165.3 1,297 817.3 1,626 2,008 1,667 1,856 2,078
FCF margin 1.3% 9.35% 5.29% 9.65% 12.19% 9.35% 9.71% 10.02%
FCF Conversion (EBITDA) 6.43% 44.23% 25.46% 46.86% 58.13% 42.83% 43.83% 44.04%
FCF Conversion (Net income) 16.75% 87.76% 56.33% 116.43% 194.81% 84.27% 83.48% 79.21%
Dividend per Share 2 - - 0.3817 - 0.1961 - 0.3348 -
Announcement Date 2/26/20 2/24/21 2/23/22 2/22/23 2/21/24 - - -
1MXN in Million2MXN
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 4,063 4,015 4,324 4,349 4,171 4,178 4,370 4,393 3,525 4,197 - - - 4,637 4,900
EBITDA 889.9 826.6 892 912.4 839.9 867.3 920.1 933.7 732.3 935.6 - - - 996.4 1,059
EBIT 1 850.7 775.2 839.8 859.4 788.4 868.8 871.1 885.8 663.5 857.2 937.4 951.7 781.5 931 1,003
Operating Margin 20.94% 19.31% 19.42% 19.76% 18.9% 20.79% 19.93% 20.16% 18.82% 20.42% - - - 20.08% 20.48%
Earnings before Tax (EBT) 1 604.5 498.8 613.6 614.2 534.8 491.3 574.9 548.3 70.58 517 745.8 769.7 599.5 760.6 818.7
Net income 1 359.2 339.2 404.7 399.3 253.6 358 417.4 370.7 -115.5 372.1 492.2 508 395.7 502 540.3
Net margin 8.84% 8.45% 9.36% 9.18% 6.08% 8.57% 9.55% 8.44% -3.28% 8.87% - - - 10.83% 11.03%
EPS 2 0.3600 0.3400 0.4000 0.4000 - 0.3700 0.4300 0.3900 -0.1200 0.3600 0.4698 0.4874 0.4838 0.4790 0.5156
Dividend per Share 2 0.3817 - 0.3817 - - - 0.1961 0.1961 - - - - - - -
Announcement Date 2/23/22 4/27/22 7/27/22 10/26/22 2/22/23 4/26/23 7/26/23 10/25/23 2/21/24 4/24/24 - - - - -
1MXN in Million2MXN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 5,112 4,320 4,650 4,870 4,520 3,446 2,828 2,888
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.988 x 1.473 x 1.449 x 1.403 x 1.309 x 0.8854 x 0.6678 x 0.6121 x
Free Cash Flow 1 165 1,297 817 1,626 2,008 1,667 1,857 2,078
ROE (net income / shareholders' equity) 12.6% 16.8% 14.1% 13.8% 10.6% 15.1% 15.7% 15.5%
ROA (Net income/ Total Assets) 5.28% 7.17% 6.51% 6.45% 4.88% 7.4% 9.15% -
Assets 1 18,705 20,615 22,300 21,649 21,135 26,733 24,292 -
Book Value Per Share 2 7.870 9.200 11.00 - 9.830 12.40 14.30 -
Cash Flow per Share 0.9900 2.000 1.440 - 2.360 - - -
Capex 1 839 726 630 402 247 546 602 653
Capex / Sales 6.58% 5.23% 4.08% 2.38% 1.5% 3.06% 3.15% 3.15%
Announcement Date 2/26/20 2/24/21 2/23/22 2/22/23 2/21/24 - - -
1MXN in Million2MXN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genomma Lab Internacional, S.A.B. de C.V.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
17.77 MXN
Average target price
19.46 MXN
Spread / Average Target
+9.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. Stock Genomma Lab Internacional, S.A.B. de C.V.
+25.49% 1.03B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAB B Stock
  4. Financials Genomma Lab Internacional, S.A.B. de C.V.